NVAX vs OMER Stock Comparison

Compare NVAX vs OMER on performance, valuation, growth, fundamentals, momentum and risk; the current AIQ evidence does not show a clear headline leader.

Market data as of Nov 15, 2026 market close
NVAX
Healthcare
vs
OMER
Healthcare
NVAX
Novavax, Inc.
Price
$8.53
Day move
-2.68%
AIQ Score
-/100
Best edge
Quality
Sector
Healthcare
OMER
Omeros Corporation
Price
$17.49
Day move
-2.78%
AIQ Score
64/100
Best edge
Balanced
Sector
Healthcare

What is the main difference between NVAX and OMER?

NVAX and OMER are close on the current AIQ evidence, so the better fit depends more on objective, risk tolerance and valuation preference than on a single headline score.

AlgovestIQ AIQ Comparison

Novavax, Inc. vs Omeros Corporation

Data as of Nov 15, 2026· market close· Healthcare· Coverage 60/66 fields· High confidence
AIQ VerdictFragile

NVAX and OMER are effectively level

NVAX and OMER are effectively level on the AIQ Score; the factor table below shows where each one holds its advantage.

Evidence agreement: 0 of 4
NVAX

Novavax, Inc.

AIQ Score
—/100
AIQ Edge Score
—
OMER

Omeros Corporation

AIQ Score
64/100
AIQ Edge Score
7/10

The Algovestiq AIQ Score does not currently separate NVAX and OMER as of Nov 15, 2026. Both names are scored on the same 0–100 scale across Quality, Value, Momentum and Risk Resilience, and the factor table below shows where each one holds its advantage.

Compare Novavax, Inc. and Omeros Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

NVAX
-95.4%
OMER
+122.5%

Price return comparison

Growth of $10,000, price only

NVAX $463 · OMER $22,252

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare NVAX and OMER against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

NVAX advantage
0
OMER advantage
  • Quality62 vs 55
    NVAX +7
  • Risk Resilience38 vs 33
    NVAX +5
  • Momentum77 vs 79
    Even

Neither name separates cleanly on the covered dimensions.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

NVAX

Largest factor move: Momentum +3

No signal started or stopped since the prior session; its 6 active signals are unchanged.

OMER0 AIQ

Largest factor move: Momentum -1, not enough on its own to move the overall score.

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.76x)
  • RSI Midline Rejection — bearish, momentum, short horizon

Deeper signal detail for each name lives on its own signals page — NVAX and OMER both carry a full feed there.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

Even

Neither separates on the overall score.

Growth

OMER

OMER on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

Even

The two are level on Momentum.

Lower downside

NVAX

NVAX on Risk Resilience, by 5 points.

Analyst upside

OMER

OMER on implied upside to the consensus price target.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureNVAXOMERNote
Implied upside to target-6.2%+25.8%OMER has more room
Target dispersion0%0%Lower is tighter analyst agreement
ConsensusHoldBuyContext, not a primary driver
Analysts covering93Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

How each independent group of evidence reads the pair.

Evidence groupFavorsReading
AIQ ScoreNot coveredNot covered
FundamentalsNVAXon balancerevenue growth 20.5% vs 188.4%; EPS growth 40.6% vs -76.9%; TTM ROE 14.5% vs -25.8%; gross margin 77.3% vs 95.8%; operating margin -19.6% vs -189.5% — NVAX takes 3 of 5 decided legs, not all of them
ValuationNot coveredNot covered
TechnicalsOMERPrice vs 50-day -19.1% vs -4.3%; vs 200-day -8.7% vs 27%
Risk ResilienceNVAXRisk Resilience 38 vs 33
Analyst expectationsOMERTarget upside -6.2% vs 25.8%

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • Only 0 of 4 covered evidence groups agree. (argues the conclusion is provisional)

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

NVAXConflicted

2 bullish / 2 bearish / 2 neutral, conflicted

Only NVAX

  • ADX Trend Strengthening — neutral, trend, medium horizon
  • BB Lower Band Breach — bullish, volatility, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
OMERConflicted

1 bullish / 3 bearish / 2 neutral, conflicted

Only OMER

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.76x)
  • RSI Midline Rejection — bearish, momentum, short horizon

Both carry 3 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode, Beta Spike Warning.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

OMERNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -2.78%, AIQ 0 points).

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

NVAX leads on balance
MetricNVAXOMER
Revenue growth (YoY)20.5%188.4%
EPS growth (YoY)40.6%-76.9%
Gross margin77.3%95.8%
Operating margin-19.6%-189.5%
Return on equity (TTM)14.5%-25.8%
Debt to equity-1.36-1.63

Performance

OMER leads 4 of 6 windows
MetricNVAXOMER
1 week (5 sessions)-20.9%3.4%
1 month (20 sessions)-24.3%8%
3 months (63 sessions)5.6%0.7%
6 months (126 sessions)-5.9%42.8%
Year to date26.9%1.8%
1 year (252 sessions)18.4%153.8%

Technicals

OMER has the stronger structure
MetricNVAXOMER
RSI (14)37.647.9
ADX (14)2412.2
Price vs 50-day-19.1%-4.3%
Price vs 200-day-8.7%27%
Volatility (1M, annualized)97.1%54.9%

Risk

NVAX is the more resilient
MetricNVAXOMER
Beta2.121.6
Sharpe ratio0.561.36
Sortino ratio0.933.04
Max drawdown-34.6%-49.5%
Current drawdown-33.5%-16.9%
Annualized volatility73.6%110.8%
Value at risk (95%)-6.1%-6.7%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which has more analyst upside, NVAX or OMER?

Analyst price targets imply -6.2% upside for NVAX and +25.8% for OMER, so the Street currently favors OMER. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, NVAX or OMER?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, NVAX or OMER?

OMER on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, NVAX or OMER?

The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, NVAX or OMER?

NVAX is the more resilient of the two, so the other name carries the higher downside risk. NVAX on Risk Resilience, by 5 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is NVAX more profitable than OMER?

The profitability evidence is mixed: gross margin 77.3% vs 95.8%; operating margin -19.6% vs -189.5%; ttm roe 14.5% vs -25.8%. NVAX leads on two measures and OMER on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

What do the current signals say about NVAX and OMER?

NVAX: 2 bullish / 2 bearish / 2 neutral, conflicted. OMER: 1 bullish / 3 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on NVAX is Golden Cross Active (bullish, long horizon). On OMER it is Golden Cross Active (bullish, long horizon).

Compare NVAX and OMER with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.